US9193749B2ActiveUtilityA1
Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
Est. expiryOct 28, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Robert DezielSilvana LeitPatrick BeaulieuYves ChantignyJohn MancusoPierre TessierGideon ShapiroRichard ChesworthDavid Smil
A61P 43/00A61P 25/00A61P 25/14A61P 25/28A61P 21/00C07D 313/12C07D 403/04C07D 223/20C07D 209/08C07D 295/155C07D 413/06C07D 291/08C07D 221/12C07D 285/36C07D 223/28C07D 487/14C07D 513/04C07D 471/14C07D 487/04C07D 223/22C07D 403/14C07D 223/24C07D 279/22C07D 209/02C07D 243/24C07D 209/52C07D 498/04C07D 265/38C07D 495/04C07D 491/08C07D 281/16C07D 239/28C07C 259/10C07D 225/08C07H 13/10C07D 209/94C07D 267/20C07D 487/08C07D 279/26C07D 471/08C07D 413/12C07D 401/14C07D 223/16C07D 471/04C07D 239/34C07D 239/42C07D 267/14C07D 267/18C07D 243/38C07D 223/26C07C 259/06A61K 31/55
59
PatentIndex Score
0
Cited by
34
References
2
Claims
Abstract
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method of inhibiting histone deacetylase, comprising contacting the histone deacetylase with a pharmaceutical composition comprising:
i) (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof; and
ii) a pharmaceutically acceptable carrier, excipient, or diluent.
2. A method of inhibiting histone deacetylase, comprising contacting the histone deacetylase with (Z)-4-(dibenzo[b,f][1,4]oxazepin-11-yl)-N-hydroxybenzamide, or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.